Inivata, a UK-based cancer testing and treatment company, has raised £4m ($6m) in a round including healthcare company Johnson & Johnson’s corporate venturing unit.
Imperial Innovations led the round, which also included Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
Inivata’s technology includes TAm-Seq, which it licensed from Cancer Research Technology and the University of Cambridge, to detect and analyse genomic material from a cancer patient’s blood samples. The company is a spin-out from charity Cancer Research UK.
Keith Blundy, CEO of Cancer Research Technology, which commercialises research from the charity, said: “Developing technologies that allow clinicians to monitor how tumours respond to treatment non-invasively and in real-time forms a crucial part of Cancer Research UK’s commitment to deliver the promise of precision cancer medicine to patients.”
– Photo of Inivata team courtesy of Cambridge University